Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cyberonics balks at ANS advance

This article was originally published in The Gray Sheet

Executive Summary

VNS Therapy manufacturer says it is "not interested in any combination" in response to ANS' purchase of 14.8% of Cyberonics' common stock on Aug. 12-13 and subsequent entreaty to enter merger talks. ANS' investment came directly after Cyberonics' share price dropped 40% on the news of FDA's rejection of its VNS Therapy PMA for depression (1"The Gray Sheet" Aug. 16, 2004, p. 5). Perhaps to Cyberonics' disdain, much of the decline was regained upon ANS' proposed merger announcement: the issue rose 31% to close the week at $19.58. ANS is the third firm to publicly court Cyberonics, following discarded bids from Medtronic and St. Jude in 2000 and 1996, respectively...

You may also be interested in...

Cyberonics Rejects Second ANS Bid, Considers Offer Beneath Self-Appraisal

Advanced Neuromodulation Systems likely would need to up the ante to sway Cyberonics shareholders to accept a takeover bid after CEO Skip Cummins' rejection of initial offers as too low

Epilepsy Sales Efforts Redouble After FDA Letter Sends Blues To Cyberonics

Cyberonics will continue to screen 400 applicants for sales positions at its Houston office while working quickly to resolve the "not-approvable" status of its VNS Therapy depression claim

Abbott Launches Five-Minute POC Rapid COVID-19 Test

Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts